Naratriptan 2-Carboxylic Acid
- CAS874583-40-1
- CatalogueRS-N097005
- FormulaC18H25N3O4S
- MW379.48
On this page
Product identification
| Product name | Naratriptan 2-Carboxylic Acid |
|---|---|
| Catalogue No. | RS-N097005 |
| CAS No. | 874583-40-1 |
| Molecular formula | C18H25N3O4S |
| Molecular weight | 379.48 |
| Exact mass | 379.1566 (monoisotopic) |
| InChIKey | VNLHQZYDCHYDDL-UHFFFAOYSA-N |
| Availability | Custom synthesis— made to order, typically 3–4 weeks |
| Standard type | Impurity Reference Standards |
| Drug substance | Naratriptan |
| Storage | Refer to the certificate of analysis (COA) supplied with each lot |
| Intended use | For laboratory and research use only. Not for human or veterinary use. |
What is stated on the certificate
Content and purity are assigned per lot and stated on the certificate of analysis issued for the batch you receive — they are not a catalogue-level figure. The certificate records the tests performed, the specification applied and the result obtained for that lot.
| Field | Basis |
|---|---|
| Identity | Spectroscopic and chromatographic methods appropriate to the material |
| Purity | Chromatographic purity, area normalisation unless stated otherwise |
| Assay / content | Mass balance, corrected for the stated volatiles and residue |
| Catalogue and batch numbers | RS-N097005 / batch number on the certificate |
| Retest date | Printed on the certificate for the lot supplied |
Frequently asked
What documentation is supplied with this lot?
Is the assigned value given on an “as is” basis?
How should this material be stored?
Do you supply pack sizes other than those listed?
Finding this standard
Buyers reach this compound by CAS number, by catalogue number, through the drug substance it belongs to, or through the type of standard it is. Those routes all start here:
- Other impurities of Naratriptan
- Impurity Reference Standards of this kind
- Documents for this item (COA, SDS)
- Certificate of analysis for RS-N097005
- Request a quotation for RS-N097005
Searching another way? Send the structure, a SMILES string or the pharmacopoeial name — a CAS number is not required for a non-compendial impurity. Write to sales@rssechem.com.
Other standards of Naratriptan
All 22 further standards are listed here — every link is in the page, not loaded later.
Naratriptan
CUSTOM SYNTHESISRS-I091090Naratriptan USP Related Compound B
IN STOCKRS-N097001Naratriptan Related Compound A (HCl Salt)
IN STOCKRS-N0970032-(1H-Indol-5-yl)-N-methylethanesulfonamide
IN STOCKRS-U015271Naratriptan USP Related Compound B (Oxalate salt)
IN STOCKRS-N0970023-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
BACK ORDERRS-U053612Naratriptan USP Related Compound A
IN STOCKRS-U0102214-Hydrazinyl-N-methylbenzeneethanesulfonamide Hydrochloride
IN STOCKRS-U0672245-Bromo-3-(1-methyl-4-piperidinyl)indole
CUSTOM SYNTHESISRS-D1190295-{2-[(methylamino)sulfonyl]ethyl}1H-indole-2-carboxylic acid
IN STOCKRS-Z004M39N-Methyl-2-(3-(piperidin-4-yl)-1H-indol-5-yl)ethane-1-sulfonamide
IN STOCKRS-P025051N-Methylethenesulfonamide
IN STOCKRS-U054209N-Sulfamoylethyl Naratriptan Pyridinium
BACK ORDERRS-U042159N-Sulfamoylethyl naratriptan pyridinium(free salt form)
BACK ORDERRS-N097004Naratriptan N-Oxide
IN STOCKRS-D114026
Pharmacopoeial names (EP, USP, BP, JP) are used for identification purposes only and do not imply endorsement by those bodies. This product is supplied for laboratory and research use only — not for human or veterinary use.



![Chemical structure of 2,2-Bis-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonic Acid Methylamide](/structures/w4/QETQBFGXLWUZIW-UHFFFAOYSA-N.webp?v=11)

![Chemical structure of 2-[3-(1-Methylpiperidin-4-yl)-5-(2-methylsulfamoyl-ethyl)-indol-1-yl] ethanesulfonic Acid Methylamide](/structures/w4/IFLHJTWEUSQXKY-UHFFFAOYSA-N.webp?v=11)





![Chemical structure of 5-{2-[(methylamino)sulfonyl]ethyl}1H-indole-2-carboxylic acid](/structures/w4/MTEXQZAPESTQQQ-UHFFFAOYSA-N.webp?v=11)



![Chemical structure of N-Methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethene-1-sulfonamide](/structures/w4/HJDLMUVBTJHSPK-UHFFFAOYSA-N.webp?v=11)



